Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.

about

Exome Sequencing in a Family with Luminal-Type Breast Cancer Underpinned by Variation in the Methylation Pathway.

P2860

Q37691100-C632CCC9-515E-419C-B43B-CB1174DCB670

P2860

Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.

Item

http://www.wikidata.org/entity/Q41443052

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical Overestimation of HER ...... lar Subtyping Using BluePrint.

@en

type

Item

label

Clinical Overestimation of HER ...... lar Subtyping Using BluePrint.

@en

prefLabel

Clinical Overestimation of HER ...... lar Subtyping Using BluePrint.

@en

P1476

Clinical Overestimation of HER ...... lar Subtyping Using BluePrint.

@en

P2093

Ettienne J Myburgh

http://www.w3.org/2001/XMLSchema#string

Kathleen A Grant

http://www.w3.org/2001/XMLSchema#string

Lizanne Langenhoven

http://www.w3.org/2001/XMLSchema#string

Lize van der Merwe

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Trastuzumab--mechanism of action and use in clinical practice

Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data.

South African National Cancer Registry: Effect of withheld data from private health systems on cancer incidence estimates.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

P304

314-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JGO.2016.006072

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

M J Kotze

P577

2016-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28831439

http://www.w3.org/2001/XMLSchema#string

P921

progesterone-receptor positive breast cancer

P932

5560457

http://www.w3.org/2001/XMLSchema#string

Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.

about

P2860

P2860

Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932